AzTrials
AzTrials

Post Traumatic Stress DisorderNCT01804426

Hair Cortisol Level as a Predictor of PTSD Development

An observational study of Post Traumatic Stress Disorder, run by Shalvata Mental Health Center at 1 site in Israel.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Post-traumatic stress disorder, PTSD, is one of the most prevalent psychiatric disorders. As casualties of motor vehicle accidents, criminal acts or terrorism are arriving to the ER, it is almost impossible to conclude who will overcome his psychiatric trauma and will be able to return to his normal life course and… Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Post Traumatic Stress Disorder
How many people
0 participants
Where
1 siteIsrael
Study dates
Mar 2013to Jan 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: 50 men and women arriving at Meir medical center Emergency department, as a result of a traumatic civil event.

Who may be able to join

  • Age 18-50
  • Experienced a traumatic event fitting criterion A1 (stressor), A2 (Reaction) and at least 1 out of the B criterion in the ASD criteria in the DSM-IV-TR
  • Brought to the ER within hours of the traumatic event.
  • Signed an informed consent

Who cannot join

  • Known psychiatric disorder or current psychiatric medication
  • Complex injury or need for a complex medical treatment, such as operation, Packed RBC or admission extending 36 hours.
  • Disorientation, confusion, head injury including intra-cranial bleeding, LOC or a major neurological deficit.
  • Known disorder of the HPA axis or use of steroidal medications within the previous 3 years.
  • known neurological disease or previous brain surgery.
  • Major medical conditions or using medication known to influence the HPA or ANS Axis.
Show all 9Show fewer
  • Baldness or hair shorter than 1cm.
  • Using color dyes.
  • Pregnancy.

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • Meir Medical Center

    Kfar Saba

Other trials in Israel

About this study

Post-traumatic stress disorder, PTSD, is one of the most prevalent psychiatric disorders.

As casualties of motor vehicle accidents, criminal acts or terrorism are arriving to the ER, it is almost impossible to conclude who will overcome his psychiatric trauma and will be able to return to his normal life course and who will be thrown out of his promising life trajectory.

Read more

Current attempts to identify those who are at the greatest risk are still unsatisfactory, which comprise a therapeutic dilemma, since the interventions used to ameliorate and prevent the occurrence of PTSD in a high-risk patient, might be counter-productive and even precipitate the emergence of PTSD in lower-risk patients.

Since PTSD is closely related to the "Fight, Flight or Freeze" reaction, it has much to do with the autonomic nervous system and the major stress hormone, cortisol. Despite many studies demonstrating the involvement of those factors in the development of PTSD, various attempts to profile the direction of the association between PTSD and cortisol abnormalities have yielded conflicting results.

The introduction of a novel method of assessing the excretion of cortisol using residues in the human hair shaft, has allowed an unprecedented evaluation of its activity over a prolonged period of time.

Using this novel method of cortisol assessment, the investigators aim to identify biomarkers that will be able to aid in the prediction of PTSD development ahead of symptoms emergence, and will enhance the understanding of the physiological mechanism involved and etiology of this disorder.

Read the detailed description

Post-Traumatic Stress Disorder (PTSD) stems from an event that is perceived as a threat to the physical and psychological integrity of the individual. Despite evidence pointing at predisposing or protective factors, it is extremely difficult to predict who will develop PTSD after exposure to a traumatic event. However, it is of a paramount importance to predict such a clinical course, in order to intervene at an early stage and facilitate research that may lead to prevention of the disorder.

As certain features of PTSD closely resemble the response of the adrenergic system via the fight or flight mechanism, substantial effort was made to understand the role of the hypothalamus-pituitary-adrenal (HPA) axis and the autonomic nervous system (ANS) in the development and maintenance of this disorder.

Various studies demonstrated conflicting findings, both in the trend of the level of cortisol and in the timing of the endocrinological anomaly. Additional study assessed the effect of HPA axis suppression by dexamethasone on anxiety-related symptoms in healthy volunteers subjected to a stress test. Those participants whose HPA axis was inhibited, presented a significant increase in anxiety symptoms, compared to a control group.

Variability and lack of stability are the main disadvantages of current methods quantifying systemic cortisol levels via measurements in the plasma, urine and saliva. These shortcomings undermine the effort to understand the role of the HPA axis in PTSD. Variable timing of the tests, as well as the stress involved in psychiatric examination and phlebotomy, are also major confounders in such an effort. Recently, the introduction of a novel test of hair cortisol concentration (HCC) has enabled retrospective quantification of cortisol levels, and thus the HPA axis activity, over a prolonged period of time.

As hair grows, unbounded cortisol is incorporated into the hair shaft in a manner that correlates with the amount of unbounded plasma cortisol at that time period. Since scalp hair grows at a fairly constant rate of 1cm per month, especially in the posterior vertex area, analysis of 3cm would reflect the average level of unbounded cortisol throughout the previous 3 months. Several studies in animals and humans have established the test's stability over time, thus proving that the test reliably reflects major changes in the HPA axis. Studies evaluating this novel test in the field of mental health demonstrated variations of cortisol levels in a number of clinical populations: increased hair cortisol levels were demonstrated for a 6 month period in depressed patients compared to controls; communities exposed to the horrors of war in Uganda had elevated cortisol levels compared to Ugandan communities not living in war zones; among patients with generalized anxiety disorder (GAD), there were lower hair cortisol levels in comparison with a control population, despite similar cortisol saliva levels.

In addition to the advantage of a reliable measurement of unbound plasma cortisol levels over time, this novel test is also easy to perform, easy to store and causes minimal inconvenience to the patient with no actual risks.

The use of this novel method of testing for cortisol level over prolong periods of time enables us to study the course of the HPA axis in relation to stressors: the baseline status, the immediate aftermath and the continuous effects of the traumatic event on the axis. Such valuable information can aid in the ongoing debate, whether the baseline function of the HPA axis is a core predisposing factor or, in fact, a secondary causality of the traumatic event.

Achieving better understanding of the complex interplay between those biological mechanisms and the formation of PTSD might enable the targeting of high-risk population after traumatic exposure with pharmacological and psychological interventions.

Study Hypothesis Main Hypothesis

  1. Hair cortisol level previous to the trauma will correlate with PTSD development. Secondary Hypothesis
  2. Ratio between hair cortisol levels prior to trauma to saliva cortisol level following the traumatic event will correlate with PTSD development.
  3. Saliva cortisol level immediately after trauma will correlate with PTSD development.
  4. Hair cortisol level one month post trauma will correlate with PTSD development.
  5. Ratio between saliva cortisol levels to saliva alpha-amylase level (both taken at ER immediately after trauma) will correlate with PTSD development.
  6. Patients with a difference between hair cortisol levels 3 months prior to the traumatic event and levels during the 3 months following it, are more prone to developing PTSD.

Study Methods Prospective observational study, performed at Meir Medical Center, Kfar Saba, Israel and Shalvata Mental Health Center, Hod Hasharon, Israel.

50 men and women arriving at Meir medical center Emergency department, as a result of a traumatic civil event, will be recruited.

Participants will fill out demographic and medical history questionnaires, and a structured psychiatric interview (M.I.N.I) will be performed to exclude any active psychiatric disorder. If none of the exclusion criteria met, several procedures will be performed:

  1. Sampling hair from the posterior vortex.
  2. Sampling blood cortisol and saliva cortisol and alpha-amylase.
  3. Documenting pulse at the time of admission to the ER and 6 hours following the event.
  4. Filling a number of questionnaires: SLE (stressful life events); BDI (Beck Depression Scale); MADRSS (Montgomery-Asberg Depression Rating Scale); STAI (State \& Trait Anxiety Inventory); VAS-A, VAS-D; PDEQ (Peritraumatic Dissociation Experience Questionnaire); SASRQ (Stanford Acute Stress Reaction Questionnaire).

Psychiatric follow-up will be performed at 4 time points, in relation to the traumatic event: After 1 month, 3 months, 6 months and 12 months. During each assessment, the following procedures will be performed:

  1. Sampling hair from the posterior vortex.
  2. Filling out a number of questionnaires: BDI, MADRSS, STAI, VAS-A, VAS-D, CAPS (Clinician-Administered PTSD Scale), PSS (PTSD Symptoms Scale).

Relevance of potential study findings The proposed study will provide novel information on the role of the HPA axis in the development of PTSD. By answering this old, unresolved question the investigators will achieve an understanding of the neurobiological mechanism and may be able to predict the development of the disorder at an early, sub-clinical stage. The results of the study will also contribute to the understanding and rationale of the possibility of steroid treatment following an acute traumatic event.

Keywords
PTSD, Post Traumatic Stress Disorder, Cortisol, Alpha-Amylase, bio-Markers
Medical subject headings
Stress Disorders, Post-Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01804426
Study groupRoleWhat they receive
Trauma Exposed participants18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in PTSD Symptoms

    Change and development of PTSD symptoms from baseline using validated constructed psychiatric interview (CAPS) and self-administered questionnaire (PSS)

    Measured: 3, 6, and 12 month post recruitment

Secondary outcomes (2)
  1. ASD Development

    Assessing development of Acute Stress Disorder, using the Stanford Acute Stress Reaction Questionnaire.

    Measured: 1 month

  2. Change from Baseline in Hair Cortisol Levels

    Change in Hair Cortisol Levels from baseline at each of the assessment points (1, 3, 6 and 12 months).

    Measured: 1, 3, 6 and 12 months post recruitment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2013 (estimated)
  2. Study startMar 2013
  3. Primary completionJul 2015 (estimated)
  4. Study completionJan 2016 (estimated)

Why it stopped: Lack of funding.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01804426
Sponsor's protocol ID
MMC-12-221
Status last verified
Apr 2016
First submitted
28 Feb 2013
Last updated
20 Apr 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Post Traumatic Stress Disorder, run by Shalvata Mental Health Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 20 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in PTSD Symptoms (time frame: 3, 6, and 12 month post recruitment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in